SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby furnish the details of issue of duplicate share certificates. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Sun Pharma gets USFDA nod for drug to treat neonatal seizures
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to US FDA approval for phenobarbital sodium powder for injection. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 16, 2022 for Raksha Sudhir Valia SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the disclosure of related party transactions for the half year ended September 30, 2022 is enclosed herewith. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Lis ting Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Sun Pharma inks licensing pact with SPARC to commercialise medication in US market
The Mumbai-based drug maker has inked a pact with Sun Pharma Advanced Research Company (SPARC) to commercialise benzyl alcohol and propylene glycol-free phenobarbital sodium powder for injection in the US. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release titled 'Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US'. The Press Release shall be released after sending this letter to you.